Measurement of B cell maturation antigen-Directed CAR T Cells During TAK-573 Study Participation
Enrolling By Invitation
1 years - 99 years
Male
Phase
N/A
10 participants needed
1 Location
Brief description of study
The primary objective of this pilot study is to explore in a preliminary fashion whether
administration of TAK-573 increases the number of BCMA-specific T cells in blood samples
from patients with myeloma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple myeloma
-
Age: 1 years - 99 years
-
Gender: Male
Male or Femal Multiple myeloma
Updated on
04 Aug 2024.
Study ID: 844868
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
